Nonga H, Muhairwa A
Trop Anim Health Prod. 2009; 42(2):165-72.
PMID: 19562499
DOI: 10.1007/s11250-009-9401-0.
Parisi A, Lanzilotta S, Addante N, Normanno G, Modugno G, DAmbrosio A
Vet Res Commun. 2006; 31(1):113-23.
PMID: 17180449
DOI: 10.1007/s11259-006-3404-3.
Qin X, Razia Y, Johnson J, Stapp J, Boster D, Tsosie T
Antimicrob Agents Chemother. 2006; 50(10):3325-9.
PMID: 17005812
PMC: 1610095.
DOI: 10.1128/AAC.00548-06.
Gupta A, Nelson J, Barrett T, Tauxe R, Rossiter S, Friedman C
Emerg Infect Dis. 2004; 10(6):1102-9.
PMID: 15207064
PMC: 3323172.
DOI: 10.3201/eid1006.030635.
Shiraki Y, Shibata N, Doi Y, Arakawa Y
Emerg Infect Dis. 2004; 10(1):69-75.
PMID: 15078599
PMC: 3322752.
DOI: 10.3201/eid1001.030219.
Quinolone and macrolide resistance in Campylobacter jejuni and C. coli: resistance mechanisms and trends in human isolates.
Engberg J, Aarestrup F, Taylor D, Gerner-Smidt P, Nachamkin I
Emerg Infect Dis. 2001; 7(1):24-34.
PMID: 11266291
PMC: 2631682.
DOI: 10.3201/eid0701.010104.
Antibiotic resistance in Campylobacter strains isolated from animals, foods, and humans in Spain in 1997-1998.
Saenz Y, Zarazaga M, Lantero M, Gastanares M, Baquero F, Torres C
Antimicrob Agents Chemother. 2000; 44(2):267-71.
PMID: 10639348
PMC: 89669.
DOI: 10.1128/AAC.44.2.267-271.2000.
Fluoroquinolones: use of clinical data to aid formulary choice by the system of objective judgement analysis (SOJA) method.
Janknegt R
Pharmacoeconomics. 1994; 6(1):15-33.
PMID: 10147351
DOI: 10.2165/00019053-199406010-00003.
Pharmacoeconomics of antibacterial treatment.
Davey P, Malek M, Parker S
Pharmacoeconomics. 1992; 1(6):409-37.
PMID: 10147022
DOI: 10.2165/00019053-199201060-00003.
Evidence for an efflux pump in multidrug-resistant Campylobacter jejuni.
Charvalos E, Tselentis Y, Hamzehpour M, Kohler T, Pechere J
Antimicrob Agents Chemother. 1995; 39(9):2019-22.
PMID: 8540709
PMC: 162874.
DOI: 10.1128/AAC.39.9.2019.
Isolation of Campylobacter jejuni strains resistant to nalidixic acid and fluoroquinolones from children with diarrhea in Athens, Greece.
Chatzipanagiotou S, Papavasiliou E, Malamou-Lada E
Eur J Clin Microbiol Infect Dis. 1993; 12(7):566-8.
PMID: 8404924
DOI: 10.1007/BF01970969.
Increased resistance of enteropathogens to fluoroquinolones in Barcelona, Spain.
Navarro F, Miro E, Izquierdo C, Mirelis B, Prats G
Eur J Clin Microbiol Infect Dis. 1993; 12(8):645-6.
PMID: 8223670
DOI: 10.1007/BF01973651.
Evolution of susceptibilities of Campylobacter spp. to quinolones and macrolides.
Sanchez R, Fernandez-Baca V, Diaz M, Munoz P, Rodriguez-Creixems M, Bouza E
Antimicrob Agents Chemother. 1994; 38(9):1879-82.
PMID: 7810993
PMC: 284656.
DOI: 10.1128/AAC.38.9.1879.
Susceptibilities to 10 antimicrobial agents of 1,220 Campylobacter strains isolated from 1987 to 1993 from feces of pediatric patients.
Reina J, Ros M, Serra A
Antimicrob Agents Chemother. 1994; 38(12):2917-20.
PMID: 7695284
PMC: 188308.
DOI: 10.1128/AAC.38.12.2917.
Infectious diarrhoea.
Conlon C, Peto T
Int J Colorectal Dis. 1990; 5(4):236-40.
PMID: 2286809
DOI: 10.1007/BF00303284.
Development of resistance to quinolones in five patients with campylobacteriosis treated with norfloxacin or ciprofloxacin.
Martinetti Lucchini G, Burnens A, Altwegg M
Eur J Clin Microbiol Infect Dis. 1991; 10(11):953-7.
PMID: 1794366
DOI: 10.1007/BF02005451.
Characterization of high-level quinolone resistance in Campylobacter jejuni.
Gootz T, Martin B
Antimicrob Agents Chemother. 1991; 35(5):840-5.
PMID: 1649570
PMC: 245117.
DOI: 10.1128/AAC.35.5.840.
Erysipelas-like skin lesions associated with Campylobacter jejuni septicemia in patients with hypogammaglobulinemia.
Kerstens P, Endtz H, Meis J, Oyen W, Koopman R, van den Broek P
Eur J Clin Microbiol Infect Dis. 1992; 11(9):842-7.
PMID: 1468426
DOI: 10.1007/BF01960888.
Emergence of resistance to erythromycin and fluoroquinolones in thermotolerant Campylobacter strains isolated from feces 1987-1991.
Reina J, Borrell N, Serra A
Eur J Clin Microbiol Infect Dis. 1992; 11(12):1163-6.
PMID: 1291314
DOI: 10.1007/BF01961137.
